OUR BUSINESS

DirectSeq Biosciences Inc. (DSI) is a new bio-startup and has patented mass spectrometry-based sequencing technologies that are complementary to current high throughput sequencing
technologies.

DSI is unique positioned and experienced in direct sequencing of RNAs de novo and systematic mapping of RNA modifications quantitatively, and thus DSI is able to decipher the true informational content of RNA, including both four (4) canonical nucleotides (A, C, G, and U) or various modified nucleotides (>170 different modification types), that is a big challenge in RNA sequencing and no other sequencing method is currently capable of.

This biotech company is now seeking highly motivated personnel to develop sequencing business and grow it into a major sequencing platform company in the genomics industry.